Welcome to our dedicated page for Progyny news (Ticker: PGNY), a resource for investors and traders seeking the latest updates and insights on Progyny stock.
Progyny, Inc. (PGNY) generates a steady flow of news as a global leader in women’s health and family building solutions listed on the Nasdaq Global Select Market. Company updates frequently focus on fertility and women’s health benefits, research on employee and member needs, and financial performance, giving investors and benefits professionals insight into how Progyny’s model is evolving.
News coverage commonly includes quarterly earnings results and financial guidance, which are also referenced in the company’s Form 8-K filings. These releases discuss revenue from fertility benefit services and pharmacy benefit services, member engagement trends, client additions, and key metrics such as assisted reproductive treatment cycles and utilization rates. Investors following PGNY news can see how changes in client count, covered lives, and engagement influence the company’s reported results and outlook.
Progyny also issues news about new programs and product expansions. For example, it has announced pregnancy, postpartum, and menopause programs for global employers that complement its existing global fertility and family building offering, along with details on features such as Global Care Advocates, knowledge centers, and country-specific navigator support. These announcements provide context on how Progyny is extending its reach across the women’s health continuum and into global markets.
Another important category of news involves research and thought leadership. Progyny has released studies on men’s fertility experiences and on gaps between employee expectations and employer offerings in women’s health benefits, conducted with Dynata. These stories highlight barriers such as stigma, cost, and benefit complexity, and they underscore the company’s focus on data-driven insights for employers.
Additional news items may cover conference participation, leadership recognition, and partnerships, such as appearances at healthcare conferences and recognition of the CEO as a Champion for Women’s Health by the World Economic Forum and the Global Alliance for Women’s Health. For anyone tracking PGNY, this news page offers a centralized view of operational, financial, and strategic developments over time.
Kindbody, a leading fertility clinic network, announces Founder Gina Bartasi's return as CEO amidst significant company growth. Expected 2024 revenue is projected between $225-250 million, achieving profitability after years of investment. Key promotions include Gina Bruzzichesi to President and Haleigh Tebben to Chief Commercial Officer. Kindbody, serving 121 employers and over 3.1 million lives, operates 35 clinics globally. The company's proprietary tech platform, KindEMR, enhances care standardization and patient experience. Their AI initiatives aim to optimize fertility treatment outcomes.
Progyny, a leading provider of fertility and family building benefits, announced that CEO Pete Anevski will speak at the Jefferies Global Healthcare Conference. The event will take place on June 5, 2024, at 9:00 A.M. Eastern Time. The session will be accessible via a live audiocast, with a replay available on the company's website.
Progyny (Nasdaq: PGNY) announced a new share repurchase program to buy back up to $100 million of its common stock. This follows a previous program announced on February 29, 2024. The repurchase will be funded via existing cash balances and carried out through open market transactions, which may include Rule 10b5-1 plans under the Securities Exchange Act of 1934. The program's execution will depend on various factors such as stock price and market conditions. The company has the discretion to suspend or discontinue the program at any time, with no guaranteed amount of shares to be repurchased or specific prices disclosed.
Progyny (Nasdaq: PGNY), an innovative provider of fertility, family building, and women's health benefits, announced participation in two key healthcare conferences. On May 15, 2024, at 5:00 PM PT / 8:00 PM ET, Progyny executives will join a fireside chat at the BofA Securities 2024 Healthcare Conference. Additionally, they will partake in the Leerink Partners Healthcare Crossroads Conference on May 29, 2024, at 1:00 PM CT / 2:00 PM ET. Live audiocasts and replays will be accessible via the Events and Presentations section on the company’s website.
Progyny, Inc. announced strong Q1 2024 results with revenue of $278.1 million, a 7.6% increase from Q1 2023. Gross profit rose to $62.4 million, and net income was $16.9 million. The company saw an increase in clients and covered lives, leading to growth in fertility benefit and pharmacy benefit services revenue. Adjusted EBITDA was $50.3 million, with an 18.1% margin. Cash flow improved, and the company repurchased shares worth $26.4 million. The outlook for 2024 includes revenue of $1.23-$1.27 billion, net income of $68.4-$75.4 million, and Adjusted EBITDA of $216-$226 million.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
FAQ
What is the current stock price of Progyny (PGNY)?
What is the market cap of Progyny (PGNY)?
